SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD
Stopped early · Phase 2
Conditions studied: Sickle Cell Disease
In brief
Related donor stem cell transplantation using the alemtuzumab/ TBI platform has been shown to be a safe strategy to cure severe sickle cell disease. However, due to a lack of suitable donors, many patients cannot benefit from this strategy. Alternative donor sources are desperately needed to fill this gap. Nearly all patients will have a haploidentical family member who would be able to donate. The use of post transplantation cyclophosphamide has greatly improved the outcome of haploidentical stem cell transplantation. The investigators propose to combine this with alemtuzumab/TBI conditioning.
Key facts
- Study ID
- NCT02013375
- Run by
- Damiano Rondelli, MD
- People needed
- 2
- Starts
- 2014-04-10
- Expected to finish
- 2018-09-07
- Last updated by the study team
- 2019-08-28
Who can join
Age: 16 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Illinois Cancer Center — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.